01
Synthesis
Solid-phase peptide synthesis in an ISO-classified suite, with in-process controls at each coupling stage.
Research use only · Not for human or veterinary use
Quality programme
We publish the certificate of analysis for the exact lot you receive — not a representative batch, not a marketing summary.
01
Solid-phase peptide synthesis in an ISO-classified suite, with in-process controls at each coupling stage.
02
Preparative reverse-phase HPLC to target purity, followed by lyophilization under controlled vacuum.
03
Every lot is sent to an unaffiliated laboratory for identity confirmation and impurity profiling.
04
Vials are sealed, held at −20 °C and dispatched with an in-box temperature logger you keep.
Release specification
| Attribute | Method | Specification |
|---|---|---|
| Identity | LC-MS/MS | Confirmed vs. reference |
| Purity | RP-HPLC 214 nm | ≥ 98.0% area |
| Water content | Karl Fischer | ≤ 6.0% |
| Residual solvent | Headspace GC | Within ICH Q3C |
| Endotoxin | LAL kinetic | < 0.25 EU/mg |
| Appearance | Visual | White lyophilized cake |
Use bacteriostatic or sterile water directed down the vial wall. Do not shake — swirl until the cake fully dissolves.
Keep lyophilized material at −20 °C, desiccated and protected from light. Reconstituted solutions are typically held at 2–8 °C.
Split into single-use aliquots to avoid freeze-thaw cycling, which is the most common source of assay variance.